|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085630 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-14 09:17:54 |
|
注册时间: Date of Registration: |
2024-06-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
甲苯磺酸瑞马唑仑对儿童术后睡眠质量的影响 |
|
Public title: |
Effect of remimazolam besylate on postoperative sleep quality in children |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
甲苯磺酸瑞马唑仑对儿童术后睡眠质量的影响 |
|
Scientific title: |
Effect of remimazolam besylate on postoperative sleep quality in children |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡琼 |
研究负责人: |
胡琼 |
|
Applicant: |
Hu Qiong |
Study leader: |
Hu Qiong |
|
申请注册联系人电话: Applicant telephone: |
+86 138 5826 2763 |
研究负责人电话: Study leader's telephone: |
+86 138 5826 2763 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
49647151@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
49647151@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
宁波市海曙区柳汀街339号 |
研究负责人通讯地址: |
宁波市海曙区柳汀街339号 |
|
Applicant address: |
339 Liuting Street, Haishu District, Ningbo, Zhejiang Province, China |
Study leader's address: |
339 Liuting Street, Haishu District, Ningbo, Zhejiang Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁波大学附属妇女儿童医院 |
||
|
Applicant's institution: |
The Affiliated Women's and Children's Hospital of Ningbo University |
||
|
研究负责人所在单位: |
宁波大学附属妇女儿童医院 |
||
|
Affiliation of the Leader: |
The Affiliated Women's and Children's Hospital of Ningbo University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
EC2024-010 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宁波大学附属妇女儿童医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethic Committee of The Affiliated Women's and Children's Hospital of Ningbo University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-30 00:00:00 |
||
|
伦理委员会联系人: |
李秀秀 |
||
|
Contact Name of the ethic committee: |
Li Xiuxiu |
||
|
伦理委员会联系地址: |
宁波市海曙区柳汀街339号 |
||
|
Contact Address of the ethic committee: |
339 Liuting Street, Haishu District, Ningbo, Zhejiang Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 87083369 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
宁波大学附属妇女儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Women's and Children's Hospital of Ningbo University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
宁波市海曙区柳汀街339号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
339 Liuting Street, Haishu District, Ningbo, Zhejiang Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised fund |
||||||||||||||||||||||
|
Target disease: |
tonsil or adenoids hypertrophy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.主要目的:研究甲苯磺酸瑞马唑仑对儿童全身麻醉术后睡眠的影响 2.次要目的:研究甲苯磺酸瑞马唑仑对儿童全身麻醉术后谵妄及苏醒时间的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Primary objective: to study the effects of remimazolam besylate on postoperative sleep quality after general anaesthesia in children 2. Secondary objective: to study the effect of remimazolam besylate on postoperative delirium and recovery time after general anaesthesia in children. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1: 年龄4-12周岁 2: BMI指数14-25 kg/m2 3: ASA评分为Ι、II级 4: 行全身麻醉下扁桃体或腺样体手术; 5: 研究对象及其监护人清楚了解、自愿参加该项研究,并由研究对象监护人签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1: 4-12 years old; 2: BMI 14-25 kg/m2; 3: ASA grade Ι, II; 4: Undergoing Tonsillectomy or Adenoidectomy or both under general anaesthesia; 5: The guardian of the subject clearly understands and voluntarily participates in the study, and signs the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1: 神经精神疾病 2: 心肺疾病 3: 急性上呼吸道感染急性期/恢复期; 4: 慢性疾病病史; 5: 术前服用任何镇静药物; 6: 早产(妊娠时间不到36周); 7: 发育迟缓; 8: 任何不适用瑞马唑仑且研究者认为不宜参加此项研究的其他情况(急诊手术:低血容量、休克或者昏迷状态;计划行全身麻醉以外还需合并其他麻醉方式;感染性心脏疾病;凝血功能异常,贫血或者血小板减少;肝、肾功能异常;对苯二氮卓类药物、阿片类药物、丙泊酚、肌松类药物及其组分过敏或者禁忌者;被判定呼吸道管理有困难者)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: History of neuropsychiatric diseases 2: History of cardiopulmonary diseases 3: Acute upper respiratory tract infection in the acute stage/recovery stage 4: History of any other chronic diseases 5: Pre-operative use of any sedative drugs 6: Preterm labour (gestation less than 36 weeks ) 7: Developmental delay 8: Any other condition for which remimazolam is not indicated and which, in the opinion of the investigator, makes participation in the study inappropriate (emergency surgery: hypovolemia, shock, or coma; combination of anaesthesia in addition to planned general anaesthesia; infectious cardiac disease; coagulation abnormalities, anaemia, or thrombocytopenia; hepatic or renal abnormalities; allergies or contraindications to esketamine, opioids, propofol, muscarinic medications, and their components; and patients who have been convicted of a crime or who have been subjected to a drug or drug abuse. (allergy or contraindication; have difficulty with respiratory management) |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-06-18 00:00:00至 To 2025-06-18 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-06-18 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机:研究启动后由一名独立研究者使用excel生成随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
simple randomization: A table of random numbers was generated by an independent researcher using excel after the study was initiated. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲(对受试者和研究者盲) |
|
Blinding: |
Double-blind (blind to both subjects and investigators) |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束6个月后在中国临床试验注册中心公布 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
the trial data will be published in the ChiCtr 6-month after the trial is completed |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用纸质病历记录表记录数据,专人管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Report Form were used to record data, and the data was managed by a dedicated person |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |